Angiomyomatous hamartoma (AMH) is a rare disease with predisposition for inguinal and femoral lymph nodes. Histologically, it is characterized by replacement of lymph nodal parenchyma with irregularly distributed thick walled blood vessels, haphazardly arranged smooth muscle cells, variable amount of fat and fibrous tissue in a sclerotic lymphatic stroma. Few cases have also been reported in popliteal and sub - mandibular location. The exact pathogenesis is still not known. Although this entity is very rare, its recognition is important in discriminating it from other benign and malignant vascular lesions of lymph nodes.

Download full-text PDF

Source
http://dx.doi.org/10.4103/0377-4929.182039DOI Listing

Publication Analysis

Top Keywords

lymph nodes
12
angiomyomatous hamartoma
8
lymph
4
hamartoma lymph
4
nodes clinicopathological
4
clinicopathological study
4
study cases
4
cases review
4
review literature
4
literature angiomyomatous
4

Similar Publications

Advances in prostate-specific membrane antigen-targeted theranostics: from radionuclides to near-infrared fluorescence technology.

Front Immunol

January 2025

Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

Prostate-Specific Membrane Antigen (PSMA) is a highly expressed and structurally unique target specific to prostate cancer (PCa). Diagnostic and therapeutic approaches in nuclear medicine, coupling PSMA ligands with radionuclides, have shown significant clinical success. PSMA-PET/CT effectively identifies tumors and metastatic lymph nodes for imaging purposes, while -PSMA-617 (Pluvicto) has received FDA approval for treating metastatic castration-resistant PCa (mCRPC).

View Article and Find Full Text PDF

Background & Objective: Determination of axillary lymph-node status plays a pivotal role in decision making for breast cancer treatment. Biopsy is the current standard of care but hold risks of complications as well. We aimed to find out the correlation of sonographic features of lymph node and histo-pathological findings, to predict axillary lymph-node metastasis in breast cancer patients.

View Article and Find Full Text PDF

Background: The presence of level IV/V metastasis is a significant prognostic factor for patients with oral and oropharyngeal cancer, while level IV lymphadenopathy defines the N3 stage in nasopharyngeal carcinoma. However, the current staging system for hypopharyngeal squamous cell carcinoma (HPSCC) does not consider the location of involved nodes.

Objectives: To evaluate the risk factors and prognostic impact of level IV/V metastasis in patients with HPSCC.

View Article and Find Full Text PDF

Background: Extramedullary plasmacytoma (EMP) represents one of the rarer forms of plasma cell malignancies, capable of impacting a variety of tissues and organs throughout the body. The majority of EMP cases are predominantly found in the head and neck region, especially within the laryngopharynx, as well as in the gastrointestinal tract. While there have been documented instances of oropharyngeal involvement in EMP cases in the academic literature, it is important to note that EMP specifically affecting the uvula is exceedingly uncommon.

View Article and Find Full Text PDF

Objectives: This study aims to develop a nomogram to predict high-volume (> 5) lymph node metastases (HVLNM) in papillary thyroid carcinoma concomitant with Hashimoto's thyroiditis by combining ultrasound with clinicopathologic data.

Materials And Methods: The study reviewed 187 patients diagnosed with papillary thyroid cancer (PTC) concomitant with Hashimoto's thyroiditis from the First People's Hospital of Kunshan between March 2018 and December 2022. These patients underwent preoperative ultrasound and postoperative examinations.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!